CTAP — the Clinical Trial Analytics Platform turns a single mock-drug study definition into a complete, internally-consistent regulatory product: a simulated CDISC clinical dataset, its state-of-the-art biostatistics, and a full ICH/CTD dossier (Modules 1–5 + TMF/PM/Quality), assembled into an eCTD and gated by automated traceability + format checks. Below are the three worked products — each a genuine, gate-passing mock submission across a different target, indication, and authoring mode.
The hand-authored gold-standard dossier — a GLP-1 / Apelin dual agonist. Broad and reviewer-facing.
Open dossier hub →An anti-TL1A × IL-22R bispecific antibody. Generated clinical spine + agent-authored deep-knowledge.
Open dossier hub →An anti-CD19 × anti-CD20 B-cell depleter, generated end-to-end from one study definition then agent-enriched to full submission depth.
Open dossier hub →Mock / virtual drugs for portfolio use — never real patient data, never an actual regulatory submission.